Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Eyebright Medical Technology (Beijing) Co., Ltd.
  6. Ratings
    688050   CNE1000041J5

EYEBRIGHT MEDICAL TECHNOLOGY (BEIJING) CO., LTD.

(688050)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Investment
Trading -
ESG Refinitiv -
Financials
Sales Growth
Growth rating is based on the evolution of the turnover of the company between the last year and the three coming years according to consensus estimates
Earnings Growth
This rating is based on the expected evolution of the annual net Earnings Per Share (EPS) according to the estimates of the analysts who cover the company. The objective is to identify companies with dynamic earnings growth.
EBITDA / Sales
This rating is based on the EBITDA margin in relation to the company's sales, based on past performance and analysts' estimates for the coming years. Unlike profitability (final net profitability), the EBITDA margin does not include taxes, interest and depreciation. The higher this ratio, the better the rating.
Profitability
Profitability rating is based on net margin of the company for the current year and the next one according to consensus estimates
Finances
Finances rating is based on the evolution of the net debt of the company (debt or cash) and its Ebitda, compared to its revenue
-
Valuation
P/E ratio
Price Earnings Ratio rating compared the company’s current share price to its per-share earnings for the current fiscal year and the next one
EV / Sales
Valuation rating is based on the ratio between enterprise value and its turnover for the current fiscal year and the next one
-
Price to Book
This rating is based on the ratio of the company's share price to its book value, based on past performance and analysts' estimates for the coming years. The lower the ratio, the better the rating.
Price to Free Cash Flow
This rating is based on the ratio between the company's share price and the free cash flow per share generated by its activities, based on the past and analysts' estimates for the coming years. The lower the ratio, the better the rating.
-
Yield
"Yield" rating is based on the dividend relative to its share price
-
Momentum
Turnover review 12m
Revenue revisions (one year) rating is based on the evolution of revenue revisions of the company for the current fiscal year and the next one
Turnover review 4m
Revenue revisions (four months) rating is based on the evolution of revenue revisions of the company for the current fiscal year and the next one
Turnover review 7 days
The rating is based on the evolution of the company's revenue estimates based on historical and analysts' estimates for the coming years. In the last 7 days, the more the sales estimates have been revised upwards from a relative point of view, the better the rating.
Earnings revision 12m
EPS revisions (one year) rating is based on the evolution of EPS (earnings per share) revisions of the company for the current fiscal year and the next one
Earnings revision 4m
EPS revisions (four months) rating is based on the evolution of EPS (earnings per share) revisions of the company for the current fiscal year and the next one
Consensus
Analyst Opinion
Consensus rating is based on analyst recommendations
Potential Price Target
Potential rating is based on the average target price fixed by the consensus from Thomson Reuters
Price target revision 4m
This rating is based on the evolution of the analysts' price target over the last 4 months. The objective is to identify the companies whose price target has changed the most. The more positive this variation is, the better the rating.
Revision of opinion 4m
This rating is based on the evolution of the general opinion of analysts over the last 4 months. The objective is to identify the companies for which the analysts' consensus has changed the most. The more positive the change, the better the rating.
Revision of opinion 12m
This rating is based on the evolution of the general opinion of analysts over the last 12 months. The objective is to identify the companies for which the analyst consensus has changed the most. The more positive the change, the better the rating.
Business Predictability
Analyst Coverage
This rating is based on the number of analysts present within the consensus as well as the number of numerical estimates concerning the future evolution of the company's business analysed. The more a company is followed, the better the rating.
Divergence of Estimates
Business Predictability rating is based on the dispersion of analysts' estimates on the evolution of the company business in the coming years (range estimates)
-
Divergence of analysts' opinions
This rating measures the dispersion of the different opinions of the analysts who make up the consensus. The smaller the difference of opinion, the better the rating.
Divergence of Target Price
This rating measures the dispersion of the different price targets of the analysts who make up the consensus. The lower the target divergence, the better the rating.
Earnings quality
Earnings quality rating is based on quality of past earnings released by the company compared to analysts' estimates
-
Technical analysis
Short Term Timing
Short Term Timing rating is defined according to the positioning of the last closed trading price, within the area between the short term support and resistance on the basis of technical analysis in daily data
Middle Term Timing
Mid-Term Timing rating is defined according to the positioning of the last closed trading price, within the area between the mid-term support and resistance on the basis of technical analysis in daily data
Long Term Timing
Long Term Timing rating is defined according to the positioning of the last closed trading price, within the area between the long term support and resistance on the basis of technical analysis in daily data
RSI
RSI rating is based on the ranking of the security in the panel studied according to the mathematical indicator RSI 14 period
Bollinger Spread
Bollinger Bands rating is based on the ranking of the security in the panel studied according to the spread of the Bollinger bands
Unusual Volumes
Abnormal Volumes rating is based on the ranking of the security in the panel studied according to volume of the last session compared to an average session
Strengths
  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • For the past twelve months, EPS forecast has been revised upwards.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The opinion of analysts covering the stock has improved over the past four months.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 155.6 times its estimated earnings per share for the ongoing year.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
Ratings chart - Surperformance
Sector Medical Prosthetics
1st jan.Capitalisation (M$)Investor Rating
EYEBRIGHT MEDICAL TECHNOLOG..35.82%4 012
STRAUMANN HOLDING AG88.56%33 456
SONOVA HOLDING AG49.65%23 194
DEMANT A/S30.76%11 409
COCHLEAR LIMITED15.24%10 612
ÖSSUR HF.-16.41%2 591
REWALK ROBOTICS LTD.-1.52%84
DELCATH SYSTEMS, INC.-44.59%72
More Results